Change in number of shares and votes in Moberg Pharma

STOCKHOLM, December 30, 2015. The number of shares and votes in Moberg Pharma AB
(publ) has increased by 215,985 to 14,217,522 during December 2015. Therefore,
there are in total 14,217,522 shares and votes in the company as of July 31,
2015.
The reason for the increase is that warrants in Moberg Pharma have been
exercised under the company’s share-based incentive program.
For additional information contact:
Peter Wolpert, CEO, Telephone: +46 (0)70 - 735 7135, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Telephone: +46 (0)70 - 766 60 30, E-mail:
anna.ljung@mobergpharma.se

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.30 a.m. (CET) on December 30, 2015.
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex®, Domeboro®, Jointflex®, Vanquish®, and Fergon®. Kerasal
Nail®(Emtrix®or Nalox™ in certain markets) is a leading OTC treatment of nail
disorders in the U.S., Canada and several EU markets and is currently being
launched in Southeast Asia. The company is growing organically as well as
through acquisitions. Internal development programs focus on innovative drug
delivery of proven compounds and include two clinical stage assets, MOB-015
(onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has
offices in Stockholm and New Jersey and the company’s shares are listed on the
Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).